Log In
Monday 24th October 2016

Topics referred to NICE in December 2012

28th January 2013

Ministers at the Department of Health have come to an agreement about the technology appraisal topics to refer to the National Institute of Health and Clinical Excellence (NICE).

NICE will handle the appraisals for the clinical and cost effectiveness of the following drugs (to treat a number of conditions including lung cancer and multiple sclerosis): afatinib, aflibercept, alemtuzumab, dimethyl fumarate, laquinimod, teriflunomide, dabrafenib, radium-223 dichloride, sipuleucel-T and ustekinumab. NICE is expected to respond to the referrals with guidance, which is usually produced within six months to two years.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Topics referred to NICE in December 2012
Author: Jess Laurence
Article Id: 23607
Date Added: 28th Jan 2013


Inside Government

Recent Related Articles

NICE approves new cancer drugs


Add to scrapbook
Show Comments
Add comment
Find all related articles


M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2016